Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Kaubisch

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 26, 2013
Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysisNitin Ohri, Madhur K Garg, Santiago Aparo, et al.
Hepatology International|August 3, 2019
Association between neutrophil-lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinomaYifei Zhang, N Patrik Brodin, Nitin Ohri, et al.
Journal of Gastrointestinal Cancer|November 3, 2019
The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic CancerMichael Shusterman, Erin Jou, Andreas Kaubisch, et al.
Canadian Journal of Gastroenterology & Hepatology|December 12, 2018
Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma PatientsJustin Y Tang, Nitin Ohri, Rafi Kabarriti, et al.
Journal of Gastrointestinal Oncology|June 12, 2019
Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinomaJulie M Jiang, Nitin Ohri, Justin Tang, et al.
Clinical Colorectal Cancer|January 31, 2012
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancerArjun Sood, Danielle McClain, Radhashree Maitra, et al.
American Journal of Clinical Oncology|September 10, 2009
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinomaAnthony P Lam, Joseph A Sparano, Vincent Vinciguerra, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 12, 2022
Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal AdenocarcinomaAna Acuna-Villaorduna, Viswanathan Shankar, Michael Wysota, et al.
Investigational New Drugs|January 2, 2007
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancersSanjay Goel, Kavita Desai, Sirisha Karri, et al.
Investigational New Drugs|October 14, 2018
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trialsAudrey E Kam, Gopichand Pendurti, Umang H Shah, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Radiation Oncology, Biology, Physics|March 26, 2013
Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysisNitin Ohri, Madhur K Garg, Santiago Aparo, et al.
Hepatology International|August 3, 2019
Association between neutrophil-lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinomaYifei Zhang, N Patrik Brodin, Nitin Ohri, et al.
Journal of Gastrointestinal Cancer|November 3, 2019
The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic CancerMichael Shusterman, Erin Jou, Andreas Kaubisch, et al.
Canadian Journal of Gastroenterology & Hepatology|December 12, 2018
Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma PatientsJustin Y Tang, Nitin Ohri, Rafi Kabarriti, et al.
Journal of Gastrointestinal Oncology|June 12, 2019
Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinomaJulie M Jiang, Nitin Ohri, Justin Tang, et al.
Clinical Colorectal Cancer|January 31, 2012
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancerArjun Sood, Danielle McClain, Radhashree Maitra, et al.
American Journal of Clinical Oncology|September 10, 2009
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinomaAnthony P Lam, Joseph A Sparano, Vincent Vinciguerra, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 12, 2022
Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal AdenocarcinomaAna Acuna-Villaorduna, Viswanathan Shankar, Michael Wysota, et al.
Investigational New Drugs|January 2, 2007
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancersSanjay Goel, Kavita Desai, Sirisha Karri, et al.
Investigational New Drugs|October 14, 2018
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trialsAudrey E Kam, Gopichand Pendurti, Umang H Shah, et al.
Pageof 4